Anthropic Launches AI Drug Discovery Project Ahead of Major IPO
Anthropic, the AI company known for developing the Claude system, has initiated a new project focused on drug discovery. The company aims to develop drugs independently to enhance its computational tools for the pharmaceutical industry. Eric Crowder Abrams, head of life sciences at Anthropic, emphasized the importance of close collaboration with industry experts to create effective tools, stating, "To make the tools good, we need to live it just like you." Anthropic positions itself as a public benefit company, allowing it to pursue treatments for neglected diseases that large pharmaceutical companies often overlook.
About a month ago, Anthropic submitted a confidential prospectus for an initial public offering on Wall Street, expected in October. The company recently reached a valuation of $96.5 billion, surpassing all pharmaceutical companies except Eli Lilly. Its annual revenue run rate of $50 billion is also comparable to major pharma giants. However, some market observers suggest Anthropic is going public now because it believes it has peaked in revenue, facing competition from simpler, cheaper AI models. Entering the drug development market offers a stable sector with complex AI needs that require deep tech expertise, potentially helping Anthropic maintain its technological edge.
Anthropic’s drug discovery services will be integrated into a separate system called Claude Science, distinct from its main Claude model. This new system aims to simplify programming tasks for researchers, which previously required specialized skills.
In related biotech news, HistoSonics, a U.S. company developing focused ultrasound technology for cancer treatment, announced a funding round valuing it at $3.75 billion to expand commercial operations. This technology targets tumors non-invasively by concentrating ultrasound waves to destroy tissue without harming surrounding areas. The company received marketing approval in 2023 for liver tumor treatment and is exploring applications for prostate, kidney, and pancreatic tumors.
Additionally, Professor Shay Rahimipour from Bar-Ilan University developed a technology to detect early Alzheimer’s disease risk by identifying small toxic protein clusters in the brain before they appear in imaging scans. This innovation could enable earlier diagnosis and better monitoring of new drugs. The technology is currently in animal trials, with human trials planned.
Lastly, a new innovation center called RiSe.Hub opened in Sderot, focusing on solutions for disaster response and mental health rehabilitation. The center, funded by multiple partners with a 9 million shekel investment, aims to foster startups, conduct pilot projects, and boost local employment and economy through partnerships with academic and medical institutions.
